PRESS RELEASE: Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T Cell Therapy Platform in Ovarian Cancer Tumor Models
PRESS RELEASE, February 7, 2023 Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T
Carina receives ‘Safe to proceed’ letter for Phase 1/2a clinical trial of CNA3103
PRESS RELEASE Tuesday, January 24, 2023 Carina Biotech Receives FDA “Safe to Proceed” Letter for IND Application for Phase 1/2a
Carina Biotech submits an Investigational New Drug (IND) application to the US FDA for LGR5-Targeted CAR-T Cell Therapy Candidate
Carina Biotech files its first IND application for a CAR-T cell therapy targeting a solid cancer. The IND application is
Carina Biotech raises $7.5 million at first close with Tenmile as the cornerstone investor
Carina Biotech is extremely pleased to announce that it has raised $7.5 million at first close of its current funding
Carina Biotech appoints Cell Therapies to undertake manufacture of LGR5 CAR-T cells for clinical trial
Carina Biotech is pleased to announce that it has appointed Australian organisation Cell Therapies to undertake Good Manufacturing Processes (GMP)
Carina Biotech Symposium 2022 Program
Carina Biotech Symposium Program Wednesday, 18 May 2022 Hotel Grand Chancellor Adelaide + online Join from a PC, Mac, iOS
Carina Biotech inaugural symposium to be held on 18 May 2022 in Adelaide and virtually
PLEASE JOIN US on Wednesday, 18 May 2022 9:30 am – 5:00 pm for Carina Biotech's inaugural symposium Join us
Carina Biotech to showcase its LGR5 CAR-T program at the American Association for Cancer Research (AACR) Annual Meeting
Carina has had five abstracts accepted for poster presentations at the AACR Annual Meeting which will take place from April